Omeros Corp.
- Address
- 201 Elliott Avenue West
Sponsor Overview
Specializations
C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corp. supports clinical research in rare glomerular diseases affecting the kidney, with a focus on C3 glomerulopathy and idiopathic immune complex-mediated glomerulonephritis. The studies associated with this area examine immune-mediated renal injury and complement-driven inflammation.
- Complement-mediated kidney disease
- Immune complex glomerulonephritis
- Rare nephrology
These trials reflect interest in conditions where dysregulation of the complement system contributes to progressive renal damage.
Paroxysmal Nocturnal Hemoglobinuria
The sponsor funds research in paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disorder marked by complement-mediated red blood cell destruction and chronic hemolysis. The clinical program includes studies in patients with incomplete response to existing complement inhibition.
- Complement inhibition
- Hemolytic anemia
- Rare blood disorders
Research in this area centers on disease control, long-term tolerability, and persistent symptoms associated with PNH.
Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
Omeros Corp. is also involved in studies of haematopoietic stem cell transplant thrombotic microangiopathy (HSCT-TMA), a severe transplant-related complication involving microvascular injury, hemolysis, and organ dysfunction. The research includes high-risk pediatric populations.
- Transplant-associated microangiopathy
- Pediatric hematology
- Endothelial injury syndromes
This therapeutic area links transplant medicine with severe complement-related vascular complications.
Complement Biology and Immune-Mediated Inflammation
The sponsor’s research portfolio is concentrated in diseases driven by complement activation and immune-mediated inflammation, spanning renal and hematologic indications. The funded trials address disorders where overactive innate immune pathways contribute to tissue damage.
- Innate immune dysregulation
- Complement pathway disorders
- Rare disease immunology
Across these indications, the clinical program is centered on conditions with overlapping mechanisms of complement-mediated pathology.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients with Sub-optimal Response to C5 Inhibitor Ravulizumab: A Phase 2 Study |  Germany Greece | Not Recruiting |
| Evaluation of OMS906 Safety and Efficacy in Patients with C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis |  Lithuania Poland | Not Recruiting |
| Long-Term Safety, Tolerability, and Efficacy Evaluation of OMS906 in Patients with Paroxysmal Nocturnal Hemoglobinuria: An Open-Label Study | Germany | Not Recruiting |
| Phase 2 Evaluation of Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy | Germany Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 12 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases3 trials322 other sponsors
- 2.Hemic and Lymphatic Diseases1 trial249 other sponsors
Partnered Research Centres
12 centres- Address
- Exochi, 570 10 Thessaloniki
- Address
- Calle Marquesado De Santa Marta 1, 28027 Pamplona
- Address
- Albert-Einstein-Allee 23, Eselsberg, 89081 Ulm
- Address
- Klinikstrasse 33, 35392 Giessen
- Address
- Eivenių g. 2, LT-50161 Kaunas
- Address
- Carl-Neuberg-Strasse 1, Gross Buchholz, 30625 Hanover
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Omeros Corp..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.